UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549



FORM
10-K/A

(Amendment
No. 1)



[X]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For
the Fiscal Year Ended: December 31, 2016



or



[  ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



AKERS
BIOSCIENCES, INC.

(Exact
name of registrant as specified in its charter)



|New
    Jersey                      |  | 001-36268        |  | 22-2983783                
|----------------------------------- |  | ---------------- |  | --------------------------
|(State
    or other jurisdiction of |  | (Commission      |  | (I.R.S.
    Employer      
|incorporation
    or organization)  |  | File
    Number) |  | Identification
    Number)



201
Grove Road

Thorofare,
New Jersey USA 08086

(Address
of principal executive offices, including zip code)



(856)
848-8698

(Registrant’s
telephone number, including area code)



Securities
registered pursuant to Section 12(b) of the Act: None



Securities
registered pursuant to Section 12(g) of the Act: Common Stock, no par value



Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes [  ]
No [X]



Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [  ]
No [X]



Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports) and (2) has been subject to such filing requirements for the last 90 days. Yes [X] No [  ]



Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]



Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [  ]



Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.



| | Large
    Accelerated Filer [  ] |  | Accelerated
    Filer [  ]       
| | -------------------------------- |  | ---------------------------------
| |                                  |  |                                  
| | Non-Accelerated
    Filer [  ]   |  | Smaller
    reporting company [X]



Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No
[X]



The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2016, based
on a closing price of $3.22 was $14,897,365. As of April 5, 2017, the registrant had 8,853,745 shares of its common stock, no
par value per share, outstanding.



Documents
Incorporated By Reference: None.




















EXPLANATORY
NOTE



This
Amendment (the “Amendment”) to Akers Biosciences, Inc.’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2016, filed with the Securities and Exchange Commission on April 11, 2017 (the “Form 10-K”), is being
filed with the limited purpose of adding the consent of Morison Cogen LLP for the incorporation of their report contained in the
Form 10-K into the Company’s Registration Statement on Form S-3/A dated November 15, 2016 (the “Consent”). The
Consent is attached as exhibit 23.1 to the Amendment. All other items in the Form 10-K are unchanged.



Item
15. Exhibits, Financial Statement Schedules.



|Exhibit
    Number |  | Description
    of Exhibit                             
|------------------ |  | -------------------------------------------------------
|                   |  |                                                        
|23.1               |  | Consent
    of Independent Registered Accounting Firm.*



*filed
herewith















SIGNATURES



Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.



|                         | AKERS
    BIOSCIENCES, INC.
|------------------------ | ---------------------------
|                         |                            
|Date:
    April 18, 2017 | By:                        
|                         | Name:                      
|                         | Title:                     
|                         |                            
|Date:
    April 18, 2017 | By:                        
|                         | Name:                      
|                         | Title:                     



Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.



|Name                      |  | Position                   |  | Date              
|------------------------- |  | -------------------------- |  | ------------------
|                          |  |                            |  |                   
|/s/
    Thomas Knox       |  | Non-Executive
    Chairman |  | April
    18, 2017
|Thomas
    Knox           |  |                            |  |                   
|                          |  |                            |  |                   
|/s/
    Raymond Akers Jr. |  | Vice
    Chairman          |  | April
    18, 2017
|Raymond
    Akers Jr.     |  |                            |  |                   
|                          |  |                            |  |                   
|/s/
    Brandon Knox      |  | Director                   |  | April
    18, 2017
|Brandon
    Knox          |  |                            |  |                   
|                          |  |                            |  |                   
|/s/
    Robert E. Andrews |  | Director                   |  | April
    18, 2017
|Robert
    E. Andrews     |  |                            |  |                   
|                          |  |                            |  |                   
|/s/
    Dr. Raza Bokhari  |  | Director                   |  | April
    18, 2017
|Dr.
    Raza Bokhari      |  |                            |  |